Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | CPT2 | P23786 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17133406 | 0.95 | FFAR1 (0.34) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL12960957 | 0.95 | FFAR1 (0.34) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL10087911 | 0.91 | LMNA (0.33) | KMT2AL3MBTL1TDP1LMNACYP4F2 | |
| SCHEMBL16260755 | 0.85 | ABCB1 (0.38) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL17470592 | 0.82 | MGAM (0.34) | KMT2AL3MBTL1LMNAALDH1A1 | |
| SCHEMBL6897007 | 0.82 | MGAM (0.34) | KMT2AL3MBTL1LMNAALDH1A1 | |
| SCHEMBL9311001 | 0.82 | FFAR1 (0.45) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL6896381 | 0.81 | ABCB1 (0.36) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL20457453 | 0.80 | FFAR1 (0.48) | MAPTMEN1KMT2AATML3MBTL1 | |
| SCHEMBL19861329 | 0.80 | FFAR1 (0.48) | MAPTMEN1KMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140350254-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | ALKERMES PHARMA IRELAND LTD (IE) | 2014-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350254-A1 | Heterocyclic Compounds for the Treatment of Neurological and Psychological Disorders | GABBR1, GABBR2, GABRE | MAPT 165/4885MEN1 1443/4885KMT2A 1652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.